Direct generation of functional dopaminergic neurons from mouse and human fibroblasts.

Stem Cells and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.
Nature (Impact Factor: 42.35). 07/2011; 476(7359):224-7. DOI: 10.1038/nature10284
Source: PubMed

ABSTRACT Transplantation of dopaminergic neurons can potentially improve the clinical outcome of Parkinson's disease, a neurological disorder resulting from degeneration of mesencephalic dopaminergic neurons. In particular, transplantation of embryonic-stem-cell-derived dopaminergic neurons has been shown to be efficient in restoring motor symptoms in conditions of dopamine deficiency. However, the use of pluripotent-derived cells might lead to the development of tumours if not properly controlled. Here we identified a minimal set of three transcription factors--Mash1 (also known as Ascl1), Nurr1 (also known as Nr4a2) and Lmx1a--that are able to generate directly functional dopaminergic neurons from mouse and human fibroblasts without reverting to a progenitor cell stage. Induced dopaminergic (iDA) cells release dopamine and show spontaneous electrical activity organized in regular spikes consistent with the pacemaker activity featured by brain dopaminergic neurons. The three factors were able to elicit dopaminergic neuronal conversion in prenatal and adult fibroblasts from healthy donors and Parkinson's disease patients. Direct generation of iDA cells from somatic cells might have significant implications for understanding critical processes for neuronal development, in vitro disease modelling and cell replacement therapies.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: limma is an R/Bioconductor software package that provides an integrated solution for analysing data from gene expression experiments. It contains rich features for handling complex experimental designs and for information borrowing to overcome the problem of small sample sizes. Over the past decade, limma has been a popular choice for gene discovery through differential expression analyses of microarray and high-throughput PCR data. The package contains particularly strong facilities for reading, normalizing and exploring such data. Recently, the capabilities of limma have been significantly expanded in two important directions. First, the package can now perform both differential expression and differential splicing analyses of RNA sequencing (RNA-seq) data. All the downstream analysis tools previously restricted to microarray data are now available for RNA-seq as well. These capabilities allow users to analyse both RNA-seq and microarray data with very similar pipelines. Second, the package is now able to go past the traditional gene-wise expression analyses in a variety of ways, analysing expression profiles in terms of co-regulated sets of genes or in terms of higher-order expression signatures. This provides enhanced possibilities for biological interpretation of gene expression differences. This article reviews the philosophy and design of the limma package, summarizing both new and historical features, with an emphasis on recent enhancements and features that have not been previously described. © The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
    Nucleic Acids Research 01/2015; · 8.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Direct cell-reprogramming technology is based on the dominant action of cell-lineage transcription factors (TFs) in converting adult somatic cells into different cell types (Graf and Enver, 2009). This technique represents a promising avenue in the field of regenerative medicine, with the potential to generate cellular sources suitable for cell-replacement therapies (Chambers and Studer, 2011). In fact, since the groundbreaking discovery of the induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006), increasing approaches of direct cell reprogramming have been established, culminating with the development of induced cellular types for neurons, cardiomyocytes, and hepatocytes (Vierbuchen et al., 2010, Ieda et al., 2010 and Huang et al., 2011). In addition, we and others employed the forced expression of defined sets of TFs to generate specific induced neuronal sublineages for dopaminergic, cholinergic, and motor neurons (Caiazzo et al., 2011, Pfisterer et al., 2011, Kim et al., 2002, Son et al., 2011, Liu et al., 2013 and Theka et al., 2013). More recently, two groups succeeded in the generation of induced oligodendrocyte precursors by direct conversion of fibroblasts (Najm et al., 2013 and Yang et al., 2013). Surprisingly, to date, there is no report for the generation of astrocyte by means of direct cell reprogramming. Astrocytes are the most-abundant cell type in the CNS and a critical neural cell type responsible for the maintenance of brain homeostasis. Indeed, they play irreplaceable roles in neurotransmitter trafficking and recycling, nutrient and ion metabolism, regulation of blood supply, release of transmitters and growth factors, and protection against oxidative stress (Molofsky et al., 2012). Consistent with such a variety of fundamental functions exerted by astrocytes in supporting neuronal survival and function, astrocyte dysfunctions have been found to contribute to several neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, lysosomal storage diseases (Di Malta et al., 2012), and Rett syndrome (Molofsky et al., 2012). Conversely, recent data showed that transplanted astrocyte progenitors display robust survival and differentiation in the host brain and are able to decelerate the disease course in ALS and Alzheimer’s disease models (Lepore et al., 2008 and Pihlaja et al., 2008). However, current protocols rely on the isolation of astrocyte progenitors from neonatal brains with serious limitations for any therapeutic approach as the paucity of cell supply and unmatched immunoprofile with the host, leading to immune reaction and possible rejection after transplantation. Cell-reprogramming approaches, by generating astrocytes starting from adult skin fibroblasts from an immunomatched or autologous source, can represent a promising alternative system for overcoming those bottlenecks. Notably, procedures of direct iPSC differentiation into astrocytes have been established only very recently (Krencik et al., 2011, Emdad et al., 2012, Juopperi et al., 2012, Roybon et al., 2013, Serio et al., 2013 and Shaltouki et al., 2013). However, these approaches rely on the previous generation of stable and mutation-free iPSC lines, and the cell differentiation protocols are considerably time-consuming, complex, and required extensive time up to 180 days. We therefore considered that a direct reprogramming approach could have interesting advantages, providing a more practical procedure to generate astrocyte-like cells. Indeed, after the identification of the reprogramming cocktail composed by the astroglial TFs NFIA, NFIB, and SOX9, we defined a straightforward and fast (∼2 weeks) protocol to generate induced astrocytes (iAstrocytes) derived from mouse embryonic and postnatal fibroblasts. Our experiments indicate that iAstrocyte molecular phenotype and biological functions closely recapitulate that of native astrocytes, thus validating the direct reprogramming technology as an alternative for the generation of astrocytes.
    Stem Cell Reports. 12/2014; 6(1).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The upregulation of dopaminergic neuronal differentiation is necessary for stem cell therapy in Parkinson’s disease (PD). In this study, neuronal differentiation efficiency increased by more than 2 times in P19 embryonic stem cells (ESCs) induced by N-acetylcysteine (NAC) and retinoic acid (RA) as compared to RA alone, with suppressed glial differentiation. The majority of NAC-treated stem cells grafted into brains of PD mice differentiated into dopaminergic neurons and persisted well for 6 weeks. Parkinsonism was also greatly improved after grafting NAC-treated cells in comparison to cells treated with only RA. Our results strongly suggest that NAC treatment may be an effective strategy for generating stem cells fated to become dopaminergic neurons for PD clinical therapy.
    Molecular Biology 07/2013; 47(4):538-543. · 0.74 Impact Factor

Full-text (5 Sources)

Available from
Jun 4, 2014